We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
EP
26
Eversept Partners
New York
$19.2M -$2.6M -68,113 -11%
Northern Trust
27
Northern Trust
Illinois
$19.1M +$653K +17,126 +3%
Charles Schwab
28
Charles Schwab
California
$18.3M +$321K +8,413 +2%
5VM
29
5AM Venture Management
California
$16.9M – – –
EA
30
Emerald Advisers
Pennsylvania
$15.5M +$9.82M +257,773 +130%
Morgan Stanley
31
Morgan Stanley
New York
$14.8M +$10.4M +271,826 +166%
SFM
32
Sphera Funds Management
Israel
$14.2M +$4.19M +109,838 +36%
American Century Companies
33
American Century Companies
Missouri
$14.1M -$24.2K -636 -0.2%
Fisher Asset Management
34
Fisher Asset Management
Washington
$12.7M +$9.67M +253,808 +211%
N
35
Nuveen
North Carolina
$12.4M -$2.6M -68,245 -16%
Marshall Wace
36
Marshall Wace
United Kingdom
$9.41M -$42M -1,101,140 -80%
TCMG
37
TSP Capital Management Group
New Jersey
$8.42M -$53.3K -1,400 -0.6%
BBA
38
Baker Bros. Advisors
New York
$8.42M – – –
EMFAT
39
Emerald Mutual Fund Advisers Trust
Pennsylvania
$8.29M +$4.45M +116,832 +92%
Bank of America
40
Bank of America
North Carolina
$7.42M -$1.09M -28,673 -12%
Axa
41
Axa
France
$6.3M +$1.64M +43,044 +30%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$6.16M -$1.87M -48,962 -21%
RAM
43
Readystate Asset Management
Illinois
$6.1M +$6.84M +179,518 New
Jane Street
44
Jane Street
New York
$5.9M -$635K -16,659 -9%
UBS Group
45
UBS Group
Switzerland
$5.66M +$229K +6,001 +4%
TD Asset Management
46
TD Asset Management
Ontario, Canada
$5.45M -$975K -25,600 -13%
SCM
47
Silverarc Capital Management
Massachusetts
$4.93M -$8.76M -229,910 -61%
TC
48
TwinBeech Capital
New York
$4.78M +$3.94M +103,497 +280%
CM
49
Crestline Management
Texas
$4.69M +$2.01M +52,637 +62%
Barclays
50
Barclays
United Kingdom
$4.43M +$2.9M +76,207 +141%
1
2
3 4 5

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.